Coronavirus, last minute | The US studies authorizing the Ronapreve monoclonal antibody cocktail against Covid-19

The WHO has once again modified its recommendations regarding the

.

The advisory group of experts on

of the

(WHO) has recommended that patients in certain groups at risk receive a third additional dose of

anticovid

, despite the fact that the agency had asked in August for a moratorium on these inoculations of reinforcement.

The data of the coronavirus in Spain

Total figures

: 4,977,448 confirmed coronavirus cases with a diagnostic test for active infection;

There have been 86,827 deaths with a positive test as of October 10.

• 803,876 in Andalusia (11,200 dead)

• 161,616 in Aragon (3,853 dead)

• 71,003 in Asturias (2,070 dead)

• 99,803 in the Balearic Islands (965 dead)

• 95,830 in the Canary Islands (1,001 dead)

• 46,453 in Cantabria (608 dead)

• 238,933 in Castilla-La Mancha (6,475 dead)

• 299,890 in Castilla y León (7,321 dead)

• 921,841 in Catalonia (15,758 dead)

• 7,570 in Ceuta (128 dead)

• 511,551 in the Valencian Community (7,784 dead)

• 102,763 in Extremadura (1,993 dead)

• 186,863 in Galicia (2,639 dead)

• 893,471 in Madrid (16,145 dead)

• 11,038 in Melilla (108 dead)

• 141,310 in Murcia (1,739 dead)

• 82,742 in Navarra (1,248 dead)

• 261,353 in the Basque Country (4,969 dead)

• 39,542 in La Rioja (823 dead)

07.00.

EMA studies authorizing Ronapreve monoclonal antibodies against coronavirus

The European Medicines Agency (EMA) has received a request to study the possible authorization in the European Union (EU) of

, a cocktail of monoclonal antibodies developed by the firms

and

for the treatment and prevention of

.

The agency is evaluating the marketing license requested by

for the approval of the drug that combines the monoclonal antibodies

and

, to treat adults and adolescents over 12 years of age who do not require supplemental oxygen and are at increased risk of developing

serious.

This cocktail could also be used for the prevention of

in adults and adolescents older than 12 years, according to data in the hands of the Committee for Human Medicines (CHMP).

The EMA estimates that it will be able to complete its evaluation of the benefits and risks of the drug in a "reduced" period of two months, depending on the strength of the data presented by the pharmacist, and provided that no additional information is required to support the analysis.

The agency began in February a real-time review of the data of this treatment that combines monoclonal antibodies, after seeing that the "preliminary results of a study indicate a beneficial effect of the drug in reducing the amount of virus in the blood (viral load) in non-hospitalized patients "who contracted it.

According to the criteria of The Trust Project

Know more

• Coronavirus

• Covid 19

• Science and Health

• Spain

• Vaccines

CovidCoronavirus Spain today |

More than 200 detainees in a protest in Melbourne (Australia) against the confinement

Covid-19 Fear of a sixth wave: "We are not going to eradicate the virus, but we can have moderate optimism"

SaludSanidad already registers almost 300,000 'third' doses in residences and immunosuppressed

See links of interest

• The Palm

• Last News

• What

• Work calendar

• Home THE WORLD TODAY

• Master Investigation Journalism

• How to set up Chromecast

• How to delete an Instagram account

• Real Zaragoza - Huesca